Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)

v3.10.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive (Loss) Income
Retained Deficit
Beginning balance (in shares) at Dec. 31, 2016   158,829,816      
Beginning balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 $ 3,946,442 $ (53,058) $ (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 278,626       278,626
Other comprehensive income (loss) 12,719     12,719  
Stock-based Compensation 7,988   7,988    
Issuance of common stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,436 $ 239 459,197    
Issuance of Restricted Stock (in shares)   399,843      
Issuance of Restricted Stock 0 $ 4 (4)    
Ending balance (in shares) at Sep. 30, 2017   183,081,776      
Ending balance at Sep. 30, 2017 $ 2,942,661 $ 1,831 4,413,623 (40,339) (1,432,454)
Beginning balance (in shares) at Dec. 31, 2017 183,105,910 183,105,910      
Beginning balance at Dec. 31, 2017 $ 3,101,614 $ 1,831 4,416,250 (40,539) (1,275,928)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income 296,559       296,559
Other comprehensive income (loss) (5,815)     (5,815)  
Stock-based Compensation 9,654   9,654    
Shares Repurchased (in shares)   (10,505,469)      
Shares Repurchased (109,997) $ (105) (109,892)    
Issuance of Restricted Stock (in shares)   618,202      
Issuance of Restricted Stock $ 0 $ 6 (6)    
Ending balance (in shares) at Sep. 30, 2018 173,218,643 173,218,643      
Ending balance at Sep. 30, 2018 $ 3,292,015 $ 1,732 $ 4,316,006 $ (46,354) $ (979,369)